Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gefitinib Delays NSCLC Recurrence After Surgery.

Cancer discovery - 1 Jul 2017

Abstract excerpt

For patients with non-small cell lung cancer and activating EGFR mutations who have had surgery, gefitinib appears to be more effective than chemotherapy in delaying disease recurrence. In a phase III trial, patients given the EGFR inhibitor were disease-free for 10 months longer than those who received chemotherapy.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Clinical Trials, Phase III as Topic
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to Neoplasm Recurrence, Local

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 28536156
DOI: 10.1158/2159-8290.CD-NB2017-076

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gefitinib Delays NSCLC Recurrence After Surgery.PMID 28536156Read ↗

Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.Semantic proximity Read ↗

The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.Semantic proximity Read ↗

Salvage surgery for advanced non-small cell lung cancer after response to gefitinib.Semantic proximity Read ↗

Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative RecurrenceSemantic proximity Read ↗

Is radical local therapy effective in postoperative recurrent EGFR-mutated non-small cell lung cancer?Semantic proximity Read ↗

Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer.Semantic proximity Read ↗

Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations.Semantic proximity Read ↗

Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy.Semantic proximity Read ↗

Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.Semantic proximity Read ↗

The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma.Semantic proximity Read ↗

Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.